Bibliografia

  1. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-1641
  2. Pasquale LR, Walt JG, Stern LS, Wiederkehr D, Malangone E, Dolgitser M. Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data. Adv Ther 2009; 26: 947-958
  3. Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 2011; 152: 515-522
  4. Kobelt G, Texier-Richard B, Buchholz P, Bron A, Renard JP, Rouland JF, e col. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France. J Glaucoma 2010; 19: 199-206
  5. Berenson KL, Kymes S, Hollander DA, Fiscella R, Burk C, Patel VD. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma. Am J Manag Care 2011; 17(9): e365-374
  6. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007; 25: 287-308
  7. Tuulonen A. Economic considerations of the diagnosis and management for glaucoma in the developed world. Curr Opin Ophthalmol 2011; 22: 102-109
  8. Koleva D, De Compadri P, Virgili G, Nobili A, Garattini L. A critical review of the full economic evaluations of pharmacological treatments for glaucoma. J Med Econ 2008; 11: 719-741
  9. Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther 2009; 25: 555-561
  10. De Natale R, Le Pen C, Berdeaux G. Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis. J Glaucoma 2011; 20: 234-239
  11. Friström B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol 2010; 88: 37-43
  12. Lafuma A, Salmon JF, Robert J, Berdeaux G. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database. Clin Ophthalmol 2011; 5: 361-367
  13. Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye (Lond) 2009; 23: 132-140
  14. Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, e col. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Can J Ophthalmol 2008; 43: 33-41
  15. Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. Eye (Lond) 2009; 23: 1098-1110

 

Dezembro 2012